EUVIMEDEUVIMED entdecken
Crossref

Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications

Pelin Esme, Aysenur Botsali, Ercan Caliskan

Journal of Wound Care · 2025

DOI: 10.12968/jowc.2021.0365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Wound Care, 2025. Verfasst von Pelin Esme und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Health Sciences, Gulhane Training and Research Hospital, Department of Dermatology and Venereology, Ankara, Turkey. Hauptthemen laut MEDLINE: Adalimumab, Hidradenitis Suppurativa, Wound Healing, Postoperative Complications. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The combination of adalimumab and surgical interventions plays a crucial role in managing severe hidradenitis suppurativa (HS). However, there is still limited scientific evidence regarding administering adalimumab during the perioperative period. This study aimed to evaluate whether adalimumab could adversely affect postoperative complications and the total time of wound closure (TTWC) in patients undergoing cutaneous surgery for HS.

Method

In this single-centre cohort study, patients with HS were allocated to two groups. Group 1 (biological cohort) consisted of patients with HS who had continuously received adalimumab for at least three months before the procedure. Group 2 (non-biological cohort) patients underwent cutaneous surgery after only four weeks of anti-inflammatory medication. All patients were left to secondary wound healing.

Results

A total of 30 surgical sites in 20 patients were included in the study (Group 1: 15 surgical sites/nine patients; Group 2: 15 surgical sites/11 patients). Disease severity and excised skin areas were significantly higher in Group 1 (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabHidradenitis SuppurativaWound HealingPostoperative ComplicationsAnti-Inflammatory AgentsHumansMaleFemaleAdultMiddle AgedCohort Studies

Stichwörter der Autor:innen

adalimumabbiologicshidradenitis suppurativaimmunomodulationsurgerywoundwound carewound dressingwound healing

Substanzen

AdalimumabAnti-Inflammatory Agents

Autor:innen und Institutionen

  • University of Health Sciences, Gulhane Training and Research Hospital, Department of Dermatology and Venereology, Ankara, Turkey.

Zitieren

APA

Esme, P., Botsali, A., & Caliskan, E. (2025). Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications. Journal of Wound Care. https://doi.org/10.12968/jowc.2021.0365

Vancouver

Esme P, Botsali A, Caliskan E. Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications. Journal of Wound Care. 2025. doi:10.12968/jowc.2021.0365

BibTeX
@article{Esme2025,
  author = {Esme, Pelin and Botsali, Aysenur and Caliskan, Ercan},
  title = {Interruption versus continuation of adalimumab during hidradenitis surgery: secondary wound healing and postoperative complications},
  journal = {Journal of Wound Care},
  year = {2025},
  doi = {10.12968/jowc.2021.0365}
}
Kostenlos starten →